Skip to main
EXEL

Exelixis (EXEL) Stock Forecast & Price Target

Exelixis (EXEL) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 38%
Buy 19%
Hold 44%
Sell 0%
Strong Sell 0%

Bulls say

Exelixis is in a strong financial position, with an estimated firm value of ~$14.1B and ~$1.6B in cash and equivalents. The company is seeing continued growth acceleration in their Cabometyx franchise, with a leading market share in RCC and 2L+ NET. While there are risks, such as potential generic erosion and the need to generate favorable data from ongoing clinical programs, the company's momentum and promising pipeline make it a compelling investment opportunity.

Bears say

Exelixis is facing increasing competition and visibility into near-and long-term growth trends is limited, while a strong balance sheet and profitability may differentiate it from peers, questions remain about the company's ability to maintain exclusivity for their flagship drug, Cabometyx, beyond FY26. Upcoming catalysts such as the initiation of the STELLAR-201 trial and potential FDA approval for zanzalintinib may provide some market sentiment, but overall, the commercial future of the company's pipeline is uncertain.

Exelixis (EXEL) has been analyzed by 16 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 19% recommend Buy, 44% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exelixis (EXEL) Forecast

Analysts have given Exelixis (EXEL) a Buy based on their latest research and market trends.

According to 16 analysts, Exelixis (EXEL) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exelixis (EXEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.